title: Design of the PID Evaluation and Clinical Health (PEACH) Study.
abstract: This paper describes the PID Evaluation and Clinical Health Study (PEACH), a multicenter, randomized clinical trial designed to compare treatment with outpatient and inpatient antimicrobial regimens among women with pelvic inflammatory disease (PID). PEACH is the first trial to evaluate the effectiveness and cost-effectiveness of currently recommended antibiotic combinations in preventing infertility, ectopic pregnancy, chronic pelvic pain, recurrent PID, and other health outcomes. It is also the largest prospective study of PID ever conducted in North America. We describe the PEACH study's specific aims, study organization, patient selection criteria, conditions for exclusion, data collected upon entry, randomization and treatment, adherence measures, follow-up activities, quality-of-life measures, outcomes, and statistical analyses. In the first 11 months of enrollment (March 1996-January 1997), 312 women were randomized. Of eligible women, 59% consented to enroll. Participating women are primarily black (72%) and young (mean age 24 years). After a median of 5.5 months of follow-up, we were in contact with 95% of study participants. The PEACH study will provide a rationale for selecting between inpatient and outpatient antibiotic treatment, the two most common treatment strategies, for PID.
authors.affiliation: Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Ness
authors.forename: D E
authors.initials: DE
authors.lastname: Soper
authors.forename: J
authors.initials: J
authors.lastname: Peipert
authors.forename: S J
authors.initials: SJ
authors.lastname: Sondheimer
authors.forename: R L
authors.initials: RL
authors.lastname: Holley
authors.forename: R L
authors.initials: RL
authors.lastname: Sweet
authors.forename: D L
authors.initials: DL
authors.lastname: Hemsell
authors.forename: H
authors.initials: H
authors.lastname: Randall
authors.forename: S L
authors.initials: SL
authors.lastname: Hendrix
authors.forename: D C
authors.initials: DC
authors.lastname: Bass
authors.forename: S F
authors.initials: SF
authors.lastname: Kelsey
authors.forename: T J
authors.initials: TJ
authors.lastname: Songer
authors.forename: J R
authors.initials: JR
authors.lastname: Lave
mesh_terms: D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents; D003362:Cost-Benefit Analysis; D003625:Data Collection; D004359:Drug Therapy, Combination / Q000191:economics / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control; D010349:Patient Compliance; D018579:Patient Selection; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000191:economics; D017699:Pelvic Pain / Q000517:prevention & control; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000517:prevention & control; D011446:Prospective Studies; D011788:Quality of Life; D012008:Recurrence; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents